These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23253680)

  • 41. Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion.
    Connolly M; Simoens S
    Int Immunopharmacol; 2011 Sep; 11(9):1358-61. PubMed ID: 21570491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
    Kallenberg CG
    Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.
    Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B
    J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immediate adverse reactions to intravenous immunoglobulin in children: a single center experience.
    Kaba S; Keskindemirci G; Aydogmus C; Siraneci R; Erol Cipe F
    Eur Ann Allergy Clin Immunol; 2017 Jan; 49(1):11-14. PubMed ID: 28120600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.
    Borte M; Bernatowska E; Ochs HD; Roifman CM;
    Clin Exp Immunol; 2011 Jun; 164(3):357-64. PubMed ID: 21413943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group.
    Giannini EH; Lovell DJ; Silverman ED; Sundel RP; Tague BL; Ruperto N
    J Rheumatol; 1996 May; 23(5):919-24. PubMed ID: 8724309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
    J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum IgG subclass concentrations before and after administration of intravenous immunoglobulin in common variable immunodeficiency.
    Ozawa T; Motoyoshi F; Kato Y; Kondo N; Orii T
    J Clin Lab Immunol; 1992; 38(1):29-39. PubMed ID: 1343346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
    Ameratunga R; Sinclair J; Kolbe J
    Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
    Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
    Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
    Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
    Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
    Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
    Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
    Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.